Cell-Based Immunotherapy Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 4.56 Billion |
| Market Size (2029) | USD 9.16 Billion |
| CAGR (2024 - 2029) | 14.98 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cell-Based Immunotherapy Market Analysis
The Global Cell Based Immunotherapy Market size is estimated at USD 4.56 billion in 2024, and is expected to reach USD 9.16 billion by 2029, growing at a CAGR of 14.98% during the forecast period (2024-2029).
COVID-19 had a significant impact on the cell-based immunotherapy market during the initial phases owing to the factors such as delayed elective surgeries, follow-up appointments, and some types of cancer treatments being canceled or postponed as hospitals prioritized beds and care for those patients who were seriously ill with COVID-19. For instance, as per an article published in March 2022 in PubMed, affected by the epidemic, many patients who were receiving subcutaneous immunotherapy (SCIT) were compelled to discontinue or postpone it.
Interestingly, cell-based immunotherapies were used for COVID-19 treatments during the pandemic. For instance, as per an article published in June 2022 in PubMed, innovative adaptive immune cell treatment gave patients with moderate-to-severe COVID-19 a viable preventative or therapeutic option. This strategy aimed to increase security, provide safe and efficient therapy, and supplement routine therapy for all COVID-19-infected patients. Post-pandemic, the market is anticipated to witness growth due to the rising prevalence of cancer, technological advancement in developing target-based anticancer therapy, and launches and approval of different cell-based immunotherapy.
For instance, as per an American Cancer Society 2022 update, the estimated number of new cancer cases was 1.9 million in 2022 in the United States. Additionally, the advancements in products, increasing approvals, clinical trials along with partnerships and collaborations by key players are helping the market growth. In June 2022 Immuneel Therapeutics, a biotech start-up commenced patient dosing in a CAR-T trial named IMAGINE. This phase II trial, which is currently actively enlisting patients in Bengaluru for clinical trial development, is one of the first industry-sponsored CAR-T trials in India. Such clinical trial developments are expected to augment the demand for cell-based immunotherapy. Furthermore, a rise in research and development in cell-based cancer therapy is likely to drive market growth over the forecast period. For instance, as per an article published in June 2022 in Frontiers, the majority of the current evaluation-stage strategies take advantage of the safety of T-cell activation and incorporate tumor-targeting mechanisms, such as chimeric antigen receptors (CARs) or bispecific T cell engagers (bsTCEs), which is likely to be essential to achieving more robust and reliable clinical responses.
Therefore, due to several factors, the cell-based immunotherapy market is anticipated to witness growth over the analysis period. However, the high cost of technology and lack of awareness in developing markets is likely to impede the market growth.
Cell-Based Immunotherapy Market Trends
Chimeric Antigen Receptor (CAR) T-Cell Therapy Is Expected To Witness Significant Growth Over The Forecast Period
Chimeric antigen receptor (CAR) T-cell therapy is a significant advancement in cancer treatment. In this therapy, the patient's T cells are genetically engineered to express an artificial receptor that binds to a tumor antigen. CAR-T cell therapy acts against CD19-coded cancer antigens to treat B-cell cancers. The rising prevalence of cancer, technological advancement in developing target-based anti-cancer therapies, and the increased adoption of cell-based therapy for therapeutic purposes are the key driving factors in the chimeric antigen receptor (CAR) T-cell therapy segment.
For instance, as per an American Cancer Society 2022 update, an estimated 10,470 children (ages 0 to 14 years) and 5,480 adolescents (ages 15-19 years) were likely to be diagnosed with cancer in the United States in 2022.
The advancements in therapy, approvals, launches, partnerships, and acquisitions by the key market players are also likely to boost segment growth. For instance, in May 2022, The European Commission (EC) approved Janssen's CAR-T therapy, Carvykti, for adults with heavily pre-treated, relapsed, and refractory multiple myeloma, marking the treatment's first approval outside of the US. Also, in March 2021 the FDA approved Abecma (idecabtagene vicleucel), the first cell-based gene therapy to treat adult multiple myeloma patients who have not responded to at least four prior rounds of therapy. It is a genetically engineered chimeric antigen receptor (CAR) T-cell therapy directed by the B-cell maturation antigen (BCMA).
North America is Expected to Witness a Growth in the Cell Based Immunotherapy Market Over The Forecast Period
North America is expected to hold a significant market share in the global cell-based immunotherapy market due to the rising prevalence of cancer, the growing awareness of cell-based therapies, the strong presence of industry players, and better healthcare infrastructure in this region. For instance, according to an American Cancer Society 2022 update, in the United States, 290,560 new cases of breast cancer, 89,010 cases of lymphoma, 62,210 cases of pancreatic cancer, 106,180 cases of colon cancer, and 44,850 cases of rectum cancer were anticipated to be diagnosed in 2022.
Furthermore, ongoing research in cancer treatment, technological advancements, product approvals, launches, partnerships, and acquisitions by the key market players also fuels the growth of the overall regional market to a large extent. For instance, in May 2022, the U.S. Food and Drug Administration (FDA) expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The accelerated approval was granted to Novartis for the chimeric antigen receptor (CAR) T-cell therapy Kymriah (tisagenlecleucel), making it the third indication for personalized cellular therapy for cancer. It remains the only CAR-T cell therapy approved for both adult and pediatric patients.
Cell-Based Immunotherapy Industry Overview
The cell-based immunotherapy market is consolidated, moderately competitive, and has a few major players. The companies currently dominating the market are Novartis AG, Gilead Sciences, Inc (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co., Ltd, and GC Biopharma Corporation.
Cell-Based Immunotherapy Market Leaders
-
Novartis AG
-
Gilead Sciences, Inc (Kite Pharma)
-
Dendreon Pharmaceuticals LLC
-
JW CreaGene Co., Ltd
-
GC Biopharma Corporation
*Disclaimer: Major Players sorted in no particular order
Cell-Based Immunotherapy Market News
- In October 2022, Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, launched CAR T Together, a first-of-its-kind effort comprised of clinical trial investigators who represent the field of clinicians committed to supporting the development of 'off-the-shelf' (allogeneic) chimeric antigen receptor (CAR) T products to make CAR T therapy scalable and more accessible to patients with certain cancers.
- In April 2022, Gilead Company's Yescarta received FDA approval as the first CAR T-cell therapy for the initial treatment of relapsed or refractory large B-cell lymphoma (LBCL).
Cell-Based Immunotherapy Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cancer
4.2.2 Technological Advancement in Developing Target Based Anti-Cancer Therapies
4.2.3 Launches and Approval of Different Cell-based Immunotherapy Drugs
4.3 Market Restraints
4.3.1 High Cost of Technology
4.3.2 Lack of Awareness in the Developing Markets
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapy
5.1.1 Autologous Cellular Immunotherapy
5.1.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy
5.1.3 Dendritic Cell-based Vaccine Therapy
5.2 By Primary Indication
5.2.1 B-cell Malignancies
5.2.2 Prostate Cancer
5.2.3 Renal Cell Carcinoma
5.2.4 Liver Cancer
5.2.5 Other Primary Indications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Gilead Sciences, Inc (Kite Pharma)
6.1.3 GC Biopharma Corporation
6.1.4 Dendreon Pharmaceuticals LLC
6.1.5 JW CreaGene Co., Ltd
6.1.6 GC Biopharma Corporation
6.1.7 Johnson and Johnson (Janssen Global Services, LLC)
6.1.8 Pfizer Inc.
6.1.9 F. Hoffmann-La Roche Ltd
6.1.10 GlaxoSmithKline plc
6.1.11 Celyad
6.1.12 Bristol-Myers Squibb Company
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Cell-Based Immunotherapy Industry Segmentation
As per the scope of the report, cell-based immunotherapy uses a cell type from the immune system as a therapeutic agent. The cells are first removed from the body, then activated or modified, expanded, and finally re-infused into the patient in this procedure. Cell-based immunotherapy is also known as adoptive cell therapy and is used to treat cancer.
The cell-based immunotherapy market is segmented by Therapy (Autologous Cellular Immunotherapy, Chimeric Antigen Receptor (CAR) T-Cell Therapy, Dendritic Cell-based Vaccine Therapy), Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, and others) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Therapy | |
| Autologous Cellular Immunotherapy | |
| Chimeric Antigen Receptor (CAR) T-Cell Therapy | |
| Dendritic Cell-based Vaccine Therapy |
| By Primary Indication | |
| B-cell Malignancies | |
| Prostate Cancer | |
| Renal Cell Carcinoma | |
| Liver Cancer | |
| Other Primary Indications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Cell-Based Immunotherapy Market Research FAQs
How big is the Global Cell Based Immunotherapy Market?
The Global Cell Based Immunotherapy Market size is expected to reach USD 4.56 billion in 2024 and grow at a CAGR of 14.98% to reach USD 9.16 billion by 2029.
What is the current Global Cell Based Immunotherapy Market size?
In 2024, the Global Cell Based Immunotherapy Market size is expected to reach USD 4.56 billion.
Who are the key players in Global Cell Based Immunotherapy Market?
Novartis AG, Gilead Sciences, Inc (Kite Pharma), Dendreon Pharmaceuticals LLC, JW CreaGene Co., Ltd and GC Biopharma Corporation are the major companies operating in the Global Cell Based Immunotherapy Market.
Which is the fastest growing region in Global Cell Based Immunotherapy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Cell Based Immunotherapy Market?
In 2024, the North America accounts for the largest market share in Global Cell Based Immunotherapy Market.
What years does this Global Cell Based Immunotherapy Market cover, and what was the market size in 2023?
In 2023, the Global Cell Based Immunotherapy Market size was estimated at USD 3.88 billion. The report covers the Global Cell Based Immunotherapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Cell Based Immunotherapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cell Based Immunotherapy Industry Report
Statistics for the 2024 Cell Based Immunotherapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cell Based Immunotherapy analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Cell Based Immunotherapy Market Report Snapshots
